← Back to Search

Unknown

A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial (IMPROVE-HCM Trial)

Phase 2
Waitlist Available
Research Sponsored by Imbria Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

This trial is testing a new drug called IMB-1018972 to see if it is safe and effective. The drug is for patients with a specific heart condition called non-obstructive hypertrophic cardiomyopathy (HCM). It aims to help their hearts work better and reduce their symptoms.

Eligible Conditions
  • Hypertrophic Cardiomyopathy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: IMB-1018972 200mgExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
IMB-1018972
2021
Completed Phase 2
~130

Find a Location

Who is running the clinical trial?

Imbria Pharmaceuticals, Inc.Lead Sponsor
3 Previous Clinical Trials
748 Total Patients Enrolled
Paul Chamberlin, MDStudy DirectorImbria Pharmaceuticals, Inc.
6 Previous Clinical Trials
1,887 Total Patients Enrolled
Medical MonitorStudy ChairImbria Pharmaceuticals, Inc.
1,678 Previous Clinical Trials
990,228 Total Patients Enrolled
~15 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top